Philotimo Fund, LP has recently filed a Schedule 13G with the SEC, revealing its beneficial ownership of 1,425,473 shares, or approximately 3.4%, of Apyx Medical Corp's common stock. This strategic investment is noteworthy as it highlights Philotimo's growing influence in the surgical and medical instruments sector.

The filing, dated October 28, 2026, indicates that Apyx Medical Corp, headquartered in Clearwater, Florida, is engaged in the production of surgical and medical instruments and apparatus. Philotimo Fund's investment signifies a potential shift in market dynamics, as it joins other investors in the competitive landscape of medical technology.

Background

Philotimo Fund, LP is a limited partnership organized in Delaware, primarily focused on investment in various sectors. The recent filing is part of a series of disclosures that indicate the fund's active role in the market. Apyx Medical Corp, identified by the CIK 0000719135, operates under the SIC code for surgical and medical instruments and apparatus.

What the Filing Says

According to the filing, Philotimo Fund beneficially owns 1,425,473 shares of Apyx Medical Corp, representing 3.4% of the outstanding shares. The filing also notes that Philotimo is part of a group that includes Philotimo Focused Growth & Income Fund and Kanen Wealth Management LLC, which collectively hold over 5% of Apyx Medical's shares. The filing states, "Each Reporting Person disclaims beneficial ownership of the Shares that he or it does not directly own." This indicates a collaborative investment strategy among the reporting entities.

Impact

This disclosure may affect various stakeholders, including Apyx Medical's management and existing shareholders, as they assess the implications of Philotimo's investment. The presence of Kanen Wealth Management LLC, which also holds a significant stake, further emphasizes the potential for strategic influence over Apyx Medical's operations and future direction.

What's Next

The filing does not specify any immediate actions or future plans following this disclosure. However, the increased ownership by Philotimo Fund and its affiliates may lead to further developments in their investment strategy or engagement with Apyx Medical.